Strive Masiyiwa sold $1.1M of NFLX
director at NETFLIX INC. 1,002 shares at an average of $1,124.26, traded May 12, 2025, filed May 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster12 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.7%, 3m +7.6%, 6m -0.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001065280-25-000246, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +162 | $386.24 | $63k | 162 | May 13, 2025 |
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +168 | $373.47 | $63k | 330 | May 13, 2025 |
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +173 | $361.99 | $63k | 503 | May 13, 2025 |
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +179 | $348.28 | $62k | 682 | May 13, 2025 |
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +155 | $403.13 | $62k | 837 | May 13, 2025 |
| May 12, 2025 | MOption exercise Common Stock10b5-1 | +165 | $380.33 | $63k | 1,002 | May 13, 2025 |
| May 12, 2025 | SOpen-market sale Common Stock10b5-1 | -1,002 | $1,124.26 | $1.1M | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -162 | $0.00 | $0 | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -168 | $0.00 | $0 | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -173 | $0.00 | $0 | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -179 | $0.00 | $0 | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualfied Stock Option (right to buy)derivative10b5-1 | -155 | $0.00 | $0 | 0 | May 13, 2025 |
| May 12, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -165 | $0.00 | $0 | 0 | May 13, 2025 |
Related signals
Other insiders at NETFLIX INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | NETFLIX INC | Richard N Barton director | $109k 1,440 shares | -45% | |
| 0Weak | NETFLIX INC | Richard N Barton director | $56k 720 shares | -23% | |
| 63Notable | NETFLIX INC | Spencer Adam Neumann Chief Financial Officer | $701k 9,248 shares | -11% | |
| 26Weak | NETFLIX INC | Richard N Barton director | $162k 2,160 shares | -90% | |
| 70Notable | NETFLIX INC | Gregory K Peters Co-CEO | $2.0M 27,312 shares | -18% | |
| 31Weak | NETFLIX INC | David A Hyman Chief Legal Officer | $417k 5,723 shares | -2% | |
| 40Moderate | NETFLIX INC | Theodore A Sarandos Co-CEO | $9.7M 133,162 shares | -43% | |
| 15Weak | NETFLIX INC | Bradford L Smith director | $2.8M 35,990 shares | -31% | |
| 25Weak | NETFLIX INC | Reed Hastings Executive Chairman | $33M 386,700 shares | -99% | |
| 65Notable | NETFLIX INC | Spencer Adam Neumann Chief Financial Officer | $823k 9,253 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.